Oppenheimer Sticks to Its Buy Rating for Gamida Cell (GMDA)
In a report released yesterday, Mark Breidenbach from Oppenheimer reiterated a Buy rating on Gamida Cell (GMDA), with a price target of $18.00. The company’s shares closed last Monday at $4.35, close to its 52-week low of $2.93.
According to TipRanks.com, Breidenbach is a 4-star analyst with an average return of 8.9% and a 42.7% success rate. Breidenbach covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Iovance Biotherapeutics, and Allogene Therapeutics.
Gamida Cell has an analyst consensus of Moderate Buy, with a price target consensus of $18.50.
See today’s analyst top recommended stocks >>
The company has a one-year high of $13.43 and a one-year low of $2.93. Currently, Gamida Cell has an average volume of 29.62K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Gamida Cell Ltd. is a clinical stage biopharmaceutical company, which engages in the development of cell therapies that are designed to cure blood cancer and rare serious hematologic diseases. The company was founded by Tony Peled and Menashe Levy in 1998 and is headquartered in Jerusalem, Israel.